Literature DB >> 22014140

Trigeminal neuralgia and persistent idiopathic facial pain.

Mark Obermann1, Dagny Holle, Zaza Katsarava.   

Abstract

Trigeminal neuralgia (TN) and persistent idiopathic facial pain (PIFP) are two of the most puzzling orofacial pain conditions and affected patients are often very difficult to treat. TN is characterized by paroxysms of brief but severe pain followed by asymptomatic periods without pain. In some patients a constant dull background pain may persist. This constant dull pain sometimes makes the distinction from PIFP difficult. PIFP is defined as continuous facial pain, typically localized in a circumscribed area of the face, which is not accompanied by any neurological or other lesion identified by clinical examination or clinical investigations. The pain usually does not stay within the usual anatomic boundaries of the trigeminal nerve distribution and is a diagnosis of exclusion. Epidemiologic evidence on TN, and even more so on PIFP, is quite scarce, but generally both conditions are considered to be rare diseases. The etiology and underlying pathophysiology of TN, and more so PIFP, remain unknown. Treatment is based on only few randomized controlled clinical trials and insufficiently evaluated surgical procedures.

Entities:  

Mesh:

Year:  2011        PMID: 22014140     DOI: 10.1586/ern.11.156

Source DB:  PubMed          Journal:  Expert Rev Neurother        ISSN: 1473-7175            Impact factor:   4.618


  9 in total

1.  Treatment of Facial Pain with I Ching Balance Acupuncture.

Authors:  Arkady Kotlyar
Journal:  Med Acupunct       Date:  2017-12-01

Review 2.  Facial Pain Update: Advances in Neurostimulation for the Treatment of Facial Pain.

Authors:  Rajivan Maniam; Alan David Kaye; Nalini Vadivelu; Richard D Urman
Journal:  Curr Pain Headache Rep       Date:  2016-04

Review 3.  Atypical Facial Pain: a Comprehensive, Evidence-Based Review.

Authors:  Austin L Weiss; Ken P Ehrhardt; Reda Tolba
Journal:  Curr Pain Headache Rep       Date:  2017-02

4.  Risk of psychiatric disorders following trigeminal neuralgia: a nationwide population-based retrospective cohort study.

Authors:  Tung-Han Wu; Li-Yu Hu; Ti Lu; Pan-Ming Chen; Hon-Jhe Chen; Cheng-Che Shen; Chun-Hsien Wen
Journal:  J Headache Pain       Date:  2015-07-15       Impact factor: 7.277

5.  Trigeminal isolated sensory neuropathy (TISN) and FOSMN syndrome: despite a dissimilar disease course do they share common pathophysiological mechanisms?

Authors:  Giorgio Cruccu; Elena M Pennisi; Giovanni Antonini; Antonella Biasiotta; Giulia di Stefano; Silvia La Cesa; Caterina Leone; Salvatore Raffa; Claudia Sommer; Andrea Truini
Journal:  BMC Neurol       Date:  2014-12-19       Impact factor: 2.474

6.  Microvascular decompression and radiofrequency for the treatment of trigeminal neuralgia: a meta-analysis.

Authors:  Yan Li; Liqiang Yang; Jiaxiang Ni; Zhi Dou
Journal:  J Pain Res       Date:  2019-06-28       Impact factor: 3.133

7.  Leveraging high-resolution 7-tesla MRI to derive quantitative metrics for the trigeminal nerve and subnuclei of limbic structures in trigeminal neuralgia.

Authors:  Judy Alper; Alan C Seifert; Gaurav Verma; Kuang-Han Huang; Yael Jacob; Ameen Al Qadi; John W Rutland; Sheetal Patel; Joshua Bederson; Raj K Shrivastava; Bradley N Delman; Priti Balchandani
Journal:  J Headache Pain       Date:  2021-09-23       Impact factor: 7.277

8.  Linear headache: a recurrent unilateral head pain circumscribed in a line-shaped area.

Authors:  Yu Wang; Miao-Miao Tian; Xian-Hong Wang; Xiao-Qun Zhu; Ying Liu; Ya-Nan Lu; Qing-Qing Pan
Journal:  J Headache Pain       Date:  2014-06-26       Impact factor: 7.277

Review 9.  Therapeutic efficacy and safety of Botulinum Toxin A Therapy in Trigeminal Neuralgia: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Mostafa Ebraheem Morra; Ahmed Elgebaly; Ahmed Elmaraezy; Adham M Khalil; Ahmed M A Altibi; Tran Le-Huy Vu; Mostafa Reda Mostafa; Nguyen Tien Huy; Kenji Hirayama
Journal:  J Headache Pain       Date:  2016-07-05       Impact factor: 7.277

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.